Sinopharm Group Co. Ltd.
SHTDFOTCHealthcare● Active
$2.30
+$0.01(+0.44%)
Market Cap$7.2B
P/E Ratio—
52W High$2.7
52W Low$2.11
Sinopharm Group Co. Ltd. (SHTDF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SHTDF · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 19, 2026EPS Actual
$0.17
Est. $0.16 · +3.5%
Revenue
$41.33B
Est. $40.53B · +2.0%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 19, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
SHTDF reports quarterly as a OTC-listed Medical - Distribution company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $6.21B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$6.21B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 31, 2026 | $0.16 | — | — | — | $42.06B | — |
| ◌ Q2 FY2026 | Apr 23, 2026 | — | — | — | — | — | — |
| ▲ Q1 FY2026 | Mar 19, 2026 | $0.16 | $0.17 | +3.5% | $41.33B | $40.53B | +2.0% |
| ▲ Q3 FY2025 | Aug 21, 2025 | $0.14 | $1.11 | +719.8% | $286.0B | $40.53B | +605.8% |
| ◌ Q2 FY2025 | Apr 25, 2025 | — | — | — | — | — | — |
| ▼ Q1 FY2025 | Mar 20, 2025 | $0.19 | $0.15 | -23.8% | $39.69B | $40.46B | -1.9% |
| ▼ Q4 FY2024 | Oct 25, 2024 | $0.19 | $0.16 | -14.0% | $40.56B | $42.86B | -5.4% |
| ◌ Q4 FY2024 | Oct 25, 2024 | — | — | — | — | — | — |
Q3 FY2026
Aug 31, 2026
EPS Actual
—
EPS Est.
$0.16
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 23, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 19, 2026Beat
EPS Actual
$0.17
EPS Est.
$0.16
EPS Surpr.
+3.5%
Revenue
$41.33B
Q3 FY2025
Aug 21, 2025Beat
EPS Actual
$1.11
EPS Est.
$0.14
EPS Surpr.
+719.8%
Revenue
$286.0B
Q2 FY2025
Apr 25, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 20, 2025Miss
EPS Actual
$0.15
EPS Est.
$0.19
EPS Surpr.
-23.8%
Revenue
$39.69B
Q4 FY2024
Oct 25, 2024Miss
EPS Actual
$0.16
EPS Est.
$0.19
EPS Surpr.
-14.0%
Revenue
$40.56B
Q4 FY2024
Oct 25, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $1.12 | $1.12 | $1.12 | 1 |
| Q3 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2025 | $0.97 | $0.97 | $0.97 | 1 |
| Q1 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2024 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2024 | $1.40 | $1.40 | $1.40 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $1983B | $1983B | $1983B | 1 |
| Q3 FY2025 | $286B | $286B | $286B | 1 |
| Q2 FY2025 | $2083B | $2083B | $2083B | 1 |
| Q1 FY2025 | $142B | $142B | $142B | 1 |
| Q4 FY2024 | $142B | $142B | $142B | 1 |
| Q2 FY2024 | $1135B | $1135B | $1135B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 19, 2026 | +3.5% | $2.63 | $2.63 | +0.00% |
| ▲ Q3 FY2025 | Aug 21, 2025 | +719.8% | $2.29 | $2.29 | +0.00% |
| ▼ Q1 FY2025 | Mar 20, 2025 | -23.8% | $2.45 | $2.45 | +0.00% |
| ▼ Q4 FY2024 | Oct 25, 2024 | -14.0% | $1.97 | $1.97 | +0.00% |
| ▲ Q2 FY2024 | Apr 26, 2024 | +5.4% | $2.89 | $2.89 | +0.00% |
| — Q2 FY2024 | Apr 26, 2024 | — | $2.89 | $2.89 | +0.00% |
| ▼ Q1 FY2024 | Mar 22, 2024 | -58.9% | $2.76 | $2.76 | +0.00% |
| ▼ Q2 FY2023 | Jun 30, 2023 | -1.6% | $2.96 | $2.96 | +0.00% |
Q1 FY2026+0.00%
Report Date
Mar 19, 2026
EPS Beat/Miss
+3.5%
Price Before
$2.63
Price After
$2.63
Q3 FY2025+0.00%
Report Date
Aug 21, 2025
EPS Beat/Miss
+719.8%
Price Before
$2.29
Price After
$2.29
Q1 FY2025+0.00%
Report Date
Mar 20, 2025
EPS Beat/Miss
-23.8%
Price Before
$2.45
Price After
$2.45
Q4 FY2024+0.00%
Report Date
Oct 25, 2024
EPS Beat/Miss
-14.0%
Price Before
$1.97
Price After
$1.97
Q2 FY2024+0.00%
Report Date
Apr 26, 2024
EPS Beat/Miss
+5.4%
Price Before
$2.89
Price After
$2.89
Q2 FY2024+0.00%
Report Date
Apr 26, 2024
EPS Beat/Miss
—
Price Before
$2.89
Price After
$2.89
Q1 FY2024+0.00%
Report Date
Mar 22, 2024
EPS Beat/Miss
-58.9%
Price Before
$2.76
Price After
$2.76
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
-1.6%
Price Before
$2.96
Price After
$2.96
Avg Beat Reaction+0.00%
Avg Miss Reaction+0.00%
Beat Rate3 / 8 quarters
Largest Move+0.00% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SHTDF ends December
Sinopharm Group Co. Ltd. (SHTDF) most recently reported earnings on March 19, 2026 for Q1 FY2026, posting EPS of $0.17 — beating the analyst consensus of $0.16 by +3.5%. SHTDF has beaten EPS estimates for 2 consecutive quarters. The next SHTDF earnings date is expected around September 1, 2026.
Each quarter, investors track SHTDF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SHTDF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SHTDF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SHTDF earnings · 5 questionsSinopharm Group Co. Ltd.'s next earnings report is expected around September 1, 2026. SHTDF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SHTDF historically reports after market close (AMC).
SHTDF earnings datewhen is SHTDF earningsSHTDF next earnings datewhen does SHTDF report earningsSHTDF earnings calendar
▸ Source: FMP · Sinopharm Group Co. Ltd. SEC filings · US GAAP · Sinopharm Group Co. Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026